We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Stempeucel

News List

India gives nod to cell therapy for Critical Limb Ischemia (CLI) europeanpharmaceuticalreview
August 25, 2020
Stempeucel®, a cell therapy for the treatment of Critical Limb Ischemia (CLI), has been approved for commercial use in India by the Drug Controller General.
Stempeutics’ allogeneic cell therapy gets DCGI approval, Cipla to market and distribute Stempeucel expresspharma
August 21, 2020
Indicated for the treatment of CLI due to Buerger’s Disease and Atherosclerotic Peripheral Arterial Disease, it is the first allogeneic cell therapy product to be approved for commercial use in India.
Stempeutics India and Novumcella Japan to work on development co-operation of Stempeucel product for expresspharma
June 02, 2020
As per the agreement, Novumcella will initially provide regulatory support services to Stempeutics for getting approval from Pharmaceuticals and Medical Devices Agency.